PRRT2 and autoimmune disease: As previously described, abnormal activation of PKC subtypes—such as PKCα overexpression in tumors, hyperactivation of the PKCθ signaling pathway in autoimmune diseases, and loss of PKCδ function in neurodegenerative disorders—constitutes core mechanisms driving the progression of various diseases.